CO4410317A1 - Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. - Google Patents

Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.

Info

Publication number
CO4410317A1
CO4410317A1 CO95043013A CO95043013A CO4410317A1 CO 4410317 A1 CO4410317 A1 CO 4410317A1 CO 95043013 A CO95043013 A CO 95043013A CO 95043013 A CO95043013 A CO 95043013A CO 4410317 A1 CO4410317 A1 CO 4410317A1
Authority
CO
Colombia
Prior art keywords
alcoholism
selective
inhibitor
opioid antagonist
receptation
Prior art date
Application number
CO95043013A
Other languages
English (en)
Inventor
Leonard Cook
Original Assignee
Du Pont Merck Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma Co filed Critical Du Pont Merck Pharma Co
Publication of CO4410317A1 publication Critical patent/CO4410317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Abstract

1. METODO DE TRATAMIENTO PARA EL ALCOHOLISMO Y DEPENDENCIA ALCOHOLICA QUE COMPRENDE LA ADMINIS- TRACION A UN MAMIFERO DE UNA CANTIDAD TERAPEUTICA- MENTE EFECTIVA DE UNA COMBINACION SINERGISTICA DE: (i) AL MENOS UN ANTAGONISTA OPIOIDE; Y (ii) AL MENOS UN INHIBIDOR DE RECAPTACION SELECTIVA DE SE- ROTONINA. 14. UNA COMPOSICION FARMACEUTICA QUE COMPRENDE U- NA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA COM- BINACION SINERGISTICA DE: AL MENOS UN ANTAGONISTA OPIOIDE; Y (ii) AL MENOS UN INHIBIDOR DE RECAPTA- CION SELECTIVA DE SEROTONINA. 15. UNA COMPOSICION FARMACEUTICA DE LA REIVINDI- CACION 14 EN DONDE EL ANTAGONISTA OPIOIDE ANTES MENCIONADO ES SELECCIONADO DEL GRUPO QUE CONSTA DE NALTREXONA, NALMEFENO Y NALOXONA. 17. UNA COMPOSICION FARMACEUTICA DE LA REIVINDI- CACION 14 EN DONDE EL INHIBIDOR DE RECAPTACION SE- LECTIVA DE SEROTONINA ES SELECCIONADO DEL GRUPO QUE CONSTA DE FLUOXETINA, SERTRALINA, PAROXETINA, FLUROXAMINA, VENLAFAXINA Y NEFAZOLONA.
CO95043013A 1994-09-19 1995-09-19 Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. CO4410317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19

Publications (1)

Publication Number Publication Date
CO4410317A1 true CO4410317A1 (es) 1997-01-09

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95043013A CO4410317A1 (es) 1994-09-19 1995-09-19 Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.

Country Status (11)

Country Link
US (1) US5958962A (es)
EP (1) EP0782445B1 (es)
AT (1) ATE214276T1 (es)
AU (1) AU3419995A (es)
CA (1) CA2197554A1 (es)
CO (1) CO4410317A1 (es)
DE (1) DE69525847T2 (es)
DK (1) DK0782445T3 (es)
HR (1) HRP950485A2 (es)
WO (1) WO1996009047A1 (es)
ZA (1) ZA957891B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
DK0980241T3 (da) * 1997-07-01 2004-04-05 Pfizer Prod Inc Gelatineindkapslede opløsningsdosisformer af sertralin
WO2001032178A1 (en) * 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20040253627A1 (en) * 2000-07-07 2004-12-16 Grant Zimmermann System and method for multidimensional evaluation of combinations of compositions
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005070461A2 (en) 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) * 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US20100168119A1 (en) 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
MA37714A1 (fr) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Méthodes de traitement de la surcharge pondérale et de l'obésité
CN104955483A (zh) 2013-01-30 2015-09-30 法莫斯医疗公司 用低剂量药剂治疗抑郁症和其它疾病
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
US5958962A (en) 1999-09-28
DE69525847T2 (de) 2002-09-05
DK0782445T3 (da) 2002-05-06
HRP950485A2 (en) 1997-08-31
AU3419995A (en) 1996-04-09
DE69525847D1 (de) 2002-04-18
ZA957891B (en) 1997-03-19
EP0782445B1 (en) 2002-03-13
ATE214276T1 (de) 2002-03-15
CA2197554A1 (en) 1996-03-28
WO1996009047A1 (en) 1996-03-28
EP0782445A1 (en) 1997-07-09

Similar Documents

Publication Publication Date Title
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
AR023129A1 (es) Composiciones para mejorar la fertilidad
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
CA2548834A1 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
MX9401191A (es) Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
WO2004093819A3 (en) Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE60236496D1 (de) Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények